ENTX
Entera Bio Ltd.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
4.20
P/S
1299.29
EV/EBITDA
-4.19
DCF Value
$0.14
FCF Yield
-37.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
-35.7%
Operating Margin
-27450.0%
Net Margin
-27235.7%
ROE
-70.4%
ROA
-71.5%
ROIC
-218.8%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $0.00 | $-3.0M | $-0.07 |
| FY 2025 | $42.0K | $-11.4M | $-0.25 |
| Q3 2025 | $0.00 | $-3.2M | $-0.07 |
| Q2 2025 | $0.00 | $-2.7M | $-0.06 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
IL
Exchange
NASDAQ
Beta
1.54
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.